ICCPP ODM+ Unveils Ceramic Coil Disposable and Multi-category Solution Resulted from Its Digital R&D Strategy
ICCPP launched the full-range ceramic coil solution including disposable ceramic coil at Vaper Expo UK in Birmingham on May 27, 2022 -- a new category empowered by its "Digital Transformation" strategy, marking a new era in the global vape industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220528005017/en/
(Photo: Business Wire)
For the first time, ICCPP exhibited as a group and showcased its branded ODM+ solution and full-range ceramic coil solution. Adopting the Gene Tree technology, ICCPP’s ceramic coil will be integrated with the ODM+ business to promote a greater evolution in the industry. The ceramic coil, ICCPP’s first product released since it jointly launched the digital strategy with SAP and PwC, is bound to become a benchmark in the global vape industry.
Breakthrough: ceramic coil solution for disposable and multiple categories
In the vape industry, the ceramic coil technology is a key indicator of technological advancement of a company. ICCPP began to engage in the ceramic coil technology in 2019 by forming a R&D team led by "Peacock Program" talents, aiming to achieve an industry-leading level with the third or fourth generation of ceramic coil, and fully surpass the peers with the fifth or sixth generation.
Committed to becoming the leader in atomization technology, ICCPP brings a natural and pleasant vaping experience to the customers with its nanocrystalline (NC) materials and technical innovation. From thick film to thin film, from wire heating and surface heating to solid heating, ICCPP’s NC ceramic atomization technology has been constantly optimized the data model of the coil and enhancing the team's R&D strength to address the pain points in the vape coil industry. The newly launched Gene Tree thin film technology features five technical advantages, namely powder-free, improved safety, finer atomization, a longer lifespan, and an improved flavor.
As a result of the continuous endeavor of the R&D team, ICCPP recently launched the new generation of Gene Tree film technology and product applications, which, compared to the third-generation ceramic coil, has improved the flavor, increased the coil lifespan, and improved product reliability, bringing users a natural and pleasant vaping experience.
ICCPP will soon launch a disposable product equipped with the Gene Tree ceramic technology, with such features as longer-lasting flavor, more puffs, better restoration of flavor, and higher reliability, will bring revolutionary user experience, trigger a revolution in the industry, and become an industry milestone.
"Digital + technological innovation" to provide ODM + digital solution
ICCPP’s core advantages at the technical level are derived from its huge investment in scientific and technological innovation. On May 26, ICCPP announced the official launch of the "Digital Transformation Project" at its Shenzhen headquarters, becoming the world's first major company in the vape industry to cooperate with SAP and PwC. This marks that ICCPP will lead the industry into the phase of digital transformation.
The digital strategy refers to the overall digital innovation of the company integrating R&D, manufacturing, export, overseas marketing, etc. In the future, ICCPP will create an unprecedented "digital closed loop" and new digital competitiveness by creating digital R&D, digital manufacturing, digital marketing, and digital consumer experience. The mode of “digital + technological innovation” will become ICCPP’s underlying competitive advantage, including digitization + chips, digitization + fragrance, and digitization + smart manufacturing. "The company will drive development through digitalization and create new value through digitalization." Through digital transformation, the company aims to bring greater contributions to the industry and global consumers.
In order to develop ceramic coil, ICCPP quickly simulated the atomization effect by setting a data model and inputting parameters such as interface and size, so as to find the optimal configuration without sample production, thus accelerating product development and delivery. At present, ICCPP has a set of long-term plans for refillable and disposable ceramic coil products, and has reached cooperation intentions with at least 5 overseas major customers.
Mission of a leading going-out company: to empower global customers with technical innovation
ICCPP knows that customers in this era don’t need the traditional ODM anymore, but the branded ODM+. Therefore, the company has launched the new strategic partnership integrating brand positioning, user insight, product design, product development and after-sales, to guide customers to embrace new era of product customization.
Firstly, ICCPP promises to provide customers with the latest technology applications, and give them the same or even better technology as ICCPP’s own brands. Secondly, ICCPP shares all cutting-edge technologies with the entire industry chain in the strategic cooperation, including labs and institutes, automated factories, overseas user insights and global marketing services. This confidence of ICCPP comes from its rich and successful overseas experience and the ability to provide customers with one-stop services. ICCPP is committed to building two global platforms to empower customers: a truly open, Android-like vape technology platform, and a globalization platform based on years of overseas experience.
As the first strategic category after the digital upgrade, the ceramic coil solution can adapt to the full range of product lines. Emboding the industry's most advanced technologies, it is set to create a new vape category, improve user experience and bring changes to the market structure. On the one hand, ICCPP ODM+ business will undergo the digital upgrade and efficiency upgrade of the whole operation system integrating market survey, R&D, product design, order, delivery, and after-sales; on the other hand, it will establish in-depth cooperation with global customers on the ceramic coil solution. So far, ICCPP has reached cooperation intentions on this ceramic coil technology with many overseas major customers. ICCPP expects to bring more surprises to global customers and restructure the market in future.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220528005017/en/
Contact information
Media Relations: Tingkai Xu, Senior PR Manager
Mobile: 15957944779
Email: kai@voopootech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SK Capital Completes Acquisition of LISI Group’s Medical Division and Launches New Platform as Precera Medical3.11.2025 13:30:00 EET | Press release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, has completed the previously announced acquisition of LISI Group’s (Euronext: FII) Medical division (the “Transaction”). The business has relocated its headquarters to Big Lake, Minnesota and has been renamed Precera Medical (“Precera Medical” or the “Company”), marking its emergence as a leading contract development and manufacturing organization (“CDMO”) partner for blue chip medical device original equipment manufacturers (“OEMs”) and innovators. As part of the Transaction, LISI Group retained a minority stake in the Company. Precera Medical is a leading CDMO focused on the production of high-precision components and assemblies serving global medical device OEMs. The Company transforms complex designs into reliable, manufacturable solutions for the most demanding applications including surgical robotics, minimally invasive surge
ACI Worldwide Acquires European Fintech Payment Components to Augment ACI Connetic3.11.2025 13:00:00 EET | Press release
ACI Worldwide (NASDAQ:ACIW), an original innovator in global payments technology, today announced that it has acquired Payment Components, a provider of AI-powered financial messaging and Open Banking solutions. ACI will integrate Payment Components technology into ACI Connetic, accelerating the roadmap of the industry's only cloud-native unified payments platform that seamlessly integrates account-to-account (A2A) payments, card processing, and AI-powered fraud prevention within a single, modular cloud-native architecture. Founded in 2014 in Greece, Payment Components develops software for A2A payments, API management, and financial messaging, streamlining transaction orchestration without complex payment processing. Its flexible messaging layer supports a broad message set, enhancing back-office connectivity and accelerating the deployment of localized payment schemes. ACI is wholly acquiring Payment Components, including its technology, intellectual property, talent, and customer re
SLB Unveils Groundbreaking New Agentic AI Technology for the Energy Industry3.11.2025 12:00:00 EET | Press release
Global energy technology company SLB (NYSE: SLB) today announced the launch of Tela™, an agentic AI assistant purpose-built to transform the upstream energy sector. Tela leverages agentic AI to not only automate processes but transform workflows and drive better business outcomes. Tela will be embedded in SLB’s portfolio of applications and platforms, and users will interact through a simple conversational interface. This approach enables agentic AI to act as a proactive collaborator — augmenting the workforce to achieve greater productivity and efficiency at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103326704/en/ Tela follows a common five-step agentic AI loop: observe, plan, generate, act and learn. This allows agents within Tela to proactively interact with their environment, adapt to new data, and continuously improve outcomes. Whether interpreting well logs, predicting drilling issues, or optimizing equip
Philip Morris International Publishes Updated Climate Transition Plan to Achieve Net Zero by 20403.11.2025 12:00:00 EET | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced the release of its second Climate Transition Plan (CTP 2025), presenting an updated and integrated strategy to achieve net-zero greenhouse gas (GHG) emissions across its value chain by 2040. The new plan reflects PMI’s continued commitment to a low-carbon future while aligning with science, regulatory frameworks, and stakeholder expectations, and builds on its 2021 Low-Carbon Transition Plan. Further, building on its 2022 Task Force on Climate-related Financial Disclosures (TCFD) report, the CTP 2025 details the results of a comprehensive climate change risks and opportunities (CCRO) assessment PMI conducted in 2024. “This Climate Transition Plan reinforces our commitment to sustainability as a fundamental business driver at PMI—one that is integrated, performance-based, and economically grounded," said Jacek Olczak, Chief Executive Officer. "By focusing on material climate risks and opportunities, implementing cost-effe
KCAS Bio Strengthens Board of Directors with Appointment of Paul Kirchgraber and Kurt Doyle3.11.2025 10:30:00 EET | Press release
KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, is delighted to announce the appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle to its Board of Directors. Their addition marks a significant milestone in KCAS Bio’s continued growth and strategic evolution in the global life sciences industry. KCAS Bio is headquartered in the Kansas City, Kansas metropolitan area with operating sites in the greater Philadelphia area; Lyon, France; and a partnership in Melbourne, Australia. The Company is backed by Vitruvian Partners, one of the world’s leading growth-focused investment firms. Dr. Paul Kirchgraber brings decades of leadership experience in clinical research and laboratory operations. He served as Executive Vice President and CEO of Covance, Labcorp’s Drug Development Division, where he led global teams in drug and medical device development in over 60 countries. Dr. Kirchgraber has experience running global p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
